Articles On Orthocell (ASX:OCC)

Wound care company Avita Medical slumps ~19% on downgrade of its earnings guidance Infection-control medtech Next Science hit with legal action by a former employee Biotech Orthocell achieves third consecutive quarter of record revenue  ...

Orthocell achieves third consecutive quarter of record revenue, reporting $2.21 million in Q2 FY25 Growth attributed to increase in sales of its Striate+ and Remplir products Regulatory approval of Remplir in US expected in March/April 202...

Highlights:  ASX 200 Futures indicate a cautious start with a focus on upcoming inflation data from the ABS.  Global markets faced declines, with US indices reversing gains and European markets showing mixed performances.  Commodities...

The S&P/ASX 200 Health Care Index fell 1.85% in December but rose 7.51% overall in 2024  Mesoblast surged 52% in December after the US FDA approved its cell therapy Ryoncil for treatment of paediatric GvHD Percheron plunged 91% in Dece...

The S&P/ASX 200 fell 3% in December as Santa rally failed to eventuate yet again  Consumer staples led the S&P/ASX 200 sectors in December with tech leading overall in 2024 Niobium and rare earths explorer Aldoro Resources led the...

Having raised cash from the likes of Chris Ellison, Rod Jones, the McCusker family and Chris Judd, the fast-running biotech stock has been among the ASX’s best performers over the past six weeks.

From artificial intelligence (A.I) to zygotes, the biotech sector this year delivered the A to Z of excitement, intrigue, occasional disappointment and downright disaster. His virtual stethoscope on hand, Dr Boreham was on duty to diagnose...

WA biotech Orthocell has started selling its nerve repair product in Singapore, two months after the company received regulatory approval in the country.

The ASX200 closed down 0.28% at 8,330 points – finishing the session at a three-week low. Jobs data today surprised analysts, with unemployment falling to 3.9%. Now the odds of an early interest rate cut have lengthened, and the Aussie d...

Key Highlights:  Strong Global Market Performance: US and European markets show robust growth, with the Nasdaq hitting a new all-time high. The S&P 500 and European aerospace stocks also saw notable gains, setting a positive tone fo...

Orthocell (ASX:OCC) has achieved first sales of its peripheral nerve repair product Remplir in Singapore. This marks an early milestone ahead of a previously planned launch in the first quarter of 2025. Remplir is made from a collagen-based...

On Chris Judd’s Talk Ya Book today, the AFL legend sat down with Orthocell Limited (ASX:OCC) chairman John Van Der Wielen to talk about the “overnight success” of the ASX-listed biotech company and its bright future. “We wanted to start...

The S&P/ASX 200 Health Care Index rose 2.89% in November as momentum returned to the sector Health cryogenic services company Vitrafy and nerve-repair biotech Renerve debuted on the ASX  Paradigm Biopharmaceuticals rose 151% in Novembe...

ASX loses momentum after near-record high Tech stocks lead, but CSL falls; retail sales rise 0.6% in October Northern Star to buy De Grey for $5 billion   The ASX has lost some of its early momentum today, pulling back from a record high...

Orthocell (ASX:OCC), has risen more than 7% today after clearing the latest hurdle to distributing its nerve repair product in the U.S. The stock’s bull run over the last two months has seen its share price more than double as investors eye...

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds. In this episode, host Sarah Hughan tells all on Orthocell’s (ASX:OCC) nerve repair product deemed safe and effective for use in the surgical repair of per...

Orthocell US FDA 510(k) regulatory study of peripheral nerve-repair product Remplir meets all endpoints Company due to submit 510(k) application in December with US FDA approval expected in Q1 CY25 Study found use of Remplir results in hig...

“Outstanding” pivotal trial results paves the way for Orthocell to seek US approval for its Remplir nerve wrap Percheron promises Duchenne trial results by Christmas Argent Biopharma says it’s not goodbye – or au revoir   Orthocell (ASX:O...

Orthocell (ASX:OCC), a Perth-based regenerative medicine company, has successfully completed a pivotal US FDA 510(k) regulatory study for its nerve repair product, Remplir. The study validated Remplir as safe and effective for use in the su...

Orthocell Ltd (ASX: OCC) shares are starting the week with a very big bang. In morning trade, the ASX healthcare share is up 26% to a 52-week high of $1.02. Why is the ASX healthcare share soaring today? Investors have been fighting to get...

Breaking Out is a technical analysis-fuelled, short ‘n’ sharp take on chart-busting ASX stocks. Each week, Steve Collette – head of Collette Capital in Melbourne – narrows in on something that’s caught his eye.   Orthocell (ASX:OCC) Orthoce...

Highlights ASX 300 showcases top movers with significant percentage changes across sectors. Consumer Discretionary and Telecommunications drive market gains amid stable sentiment. ASX mining and energy stocks experience mixed outcomes...

Highlights Web Travel Group WEB shares rise 13.48% following strong TTV growth. Pinnacle Investment Management PNI declines after announcing $25M SPP. ASX rebounds, with all sectors closing in positive territory. The Australian sh...

ASX rises on rally across the board Israel and Hezbollah agree to 60-day ceasefire City Chic tumbles after downbeat update   The Aussie share market enjoyed a solid ride on Wednesday, driven by a broad rally as optimism from Wall Street’s...

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds. In this episode, host Sarah Hughan tells all on Orthocell’s (ASX:OCC) medical device sales in Singapore on the appointment of an exclusive distributor. It...

Orthocell (ASX:OCC) has appointed Device Technologies Asia (DVT Asia) as the exclusive distributor of its nerve repair device, Remplir, in Singapore. This marks the product's first major international expansion beyond Australia and New Zeal...

Orthocell appoints Device Technologies Asia as exclusive distributor of nerve repair product Remplir in Singapore Device Technologies has been credited with driving rapid sales of Remplir in Australia and New Zealand Orthocell said market...

Nerve-repair company Renerve is set to make its ASX debut today Renerve is developing products for repair and replacement of damaged peripheral nerves It becomes only the second nerve-repair company on the ASX, after Orthocell   When Rene...

Stockhead’s Sarah Hughan sits down with Orthocell (ASX:OCC) chairman John Van Der Wielen to get the short end of the long story on the company’s latest news. The regenerative medicine company has appointed two US-based executives to drive t...

Botanix has FDA approval for its treatment for hyperhidrosis, or excessive sweating Sufferers have not had an effective treatment for the socially debilitating disorder Broker E&P Financial Group estimates revenues of close to $100 mil...

ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results Artrya and Nyrada make key clinical advances   The S&P/ASX 200 Health Care [XHJ] index was down 0.9% gain in October. For the year, th...

Orthocell (ASX:OCC) has secured $17m in a recent capital raising initiative, aimed at funding the US launch of its flagship Remplir device. The funds will also support expansion into Singapore, Southeast Asia, and Europe, and be allocated t...

Orthocell (ASX:OCC) has announced its receipt of commitments for $17M in funding via placement to bankroll the US launch of Remplir. Remplir is a skin-like, collagen-based warp used in specific wound repairs with a view towards patient...

ASX ends very modestly lower after a mixed session Newmont and Fortescue shares drop on disappointing updates WiseTech continues its slide as investors start to grumble   Aussie shares swung to a flattish close today after earlier losses...

The nerve-repair company’s shares have been on a tear after a series of positive regulatory and operating updates.

Highlights   ASX200 index falls 1.66% in its worst day in seven weeks.   Health Care sector takes the largest hit, down 2.4%.   Wisetech bounces back 2.84% after litigation settlement. The ASX200 experienced a significant drop of...

The ASX200 closed down 1.66% at 8,205 points in its worst day in seven weeks. The local bourse shed some of the gains from recent weeks as investors took profits and re-evaluated their portfolios. Health Care suffered the biggest loss...

EBR has developed the WiSE Cardiac Resynchronization Therapy (CRT) system, the world’s first leadless pacing system for heart failure Trytamine Therapeutics is pioneering a precision approach to psychedelics, targeting precise drug blood l...

Stockhead’s Sarah Hughan sits down with Orthocell’s (ASX:OCC) CEO and MD Paul Anderson to get the short end of the long story on the company’s latest news. The company has received regulatory approval from the Health Sciences Authority in S...

  Singapore’s medical regulator this week approved Orthocell’s leading nerve-repair device Remplir Remplir shows great promise in restoring function for paraplegics and quadriplegics Orthocell estimates the potential global market at US$33...

Shares in regenerative medicine company Orthocell soared after the company received regulatory approval for its nerve repair product in Singapore.

Highlights ASX200 closed down 0.35% at 8,176 points. Iron ore prices fell as China shifted focus from construction to consumer confidence. Health Care sector gained 0.75%, while Materials dropped 1.75%. The ASX200 index closed 0.3...

The ASX200 closed down 0.35% at 8,176 points. Iron ore prices fell from US$114/tn to US$108/tn in Singapore on news the Chinese government’s stimulus will focus more on boosting domestic spending. Instead of driving new construction,...

West Australia-based regenerative medicine play Orthocell (ASX: OCC) has received regulatory approval from the Health Sciences Authority in Singapore to commence sales of its nerve repair product, Remplir. It’s the first international ap...

Orthocell gains regulatory approval from Singapore’s Health Sciences Authority for its nerve repair product Remplir It is the first major international approval for Remplir outside of Australia and New Zealand Orthocell said Singapore was...

Orthocell wins Singaporean approval for its Remplir nerve-repair product Lumos wraps up $10 million whip-round amid surge of raisings in the sector ‘Nice tidy’ Cyclopharm eyes profitability from next year as US revenues grow   It’s not th...

Orthocell achieves a second consecutive quarter of record revenue, reporting $2.03m in Q1 FY25 Revenue is up 7.82% on $1.88m achieved in Q4 FY24, showing traction with growing sales of Striate+ and Remplir Company said FDA approval of Rem...

ASX rises as banking and tech sectors lead gains Arcadium Lithium surges on potential acquisition by Rio Tinto Retail groups urge Reserve Bank to cut rates ahead of holiday sales   The ASX200 index rose by 0.7% on Monday though investors...

Mesoblast expects FDA stem cell drug approval by the first week of January ‘if not earlier’ FDA to Somnomed: ‘do you want the good news or bad news first?’ Neurotech mulls its US options after FDA’s orphan drug decision Orthocell says reve...

Healthcare stocks are doing relatively well globally in 2024
 The sector could see more recovery as Fed cuts rates
 How ASX biotechs performed in the month of September   The S&P 500 Health Care Index, a key world benchmark for health...